Flexion Therapeutics Overview
Valuation check: FLXN's ROE is 122.27%, above the Healthcare sector average of 29.33%.
Get informed when a big investor buys or sells
+ Follow122.27%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, FLXN shows a ROE of 122.27%. That is above the Healthcare sector average of 29.33%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 29.33%. Flexion Therapeutics is at 122.27%, which is higher that average. That is roughly 316.9% above the sector mean. Use the comparison chart on this page to see how FLXN stacks up against individual peers as well.
Check the historical chart to see whether FLXN's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Flexion Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Flexion Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 122.27%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 29.33%, while FLXN is at 122.27%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
